EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enhanced CTLA ‐4 blockade anti‐tumor immunity with APG ‐157 combination in a murine head and neck cancer

Daniel Sanghoon Shin iD, Saroj Basak, Mysore S Veena, Begoña Comin-Anduix, Arjun Bhattacharya, Tien S Dong, Albert Ko, Philip Han, Jonathan Jacobs, Neda A Moatamed, Luis Avila, Matteo Pellegrini und 2 weitere

Cancer Medicine · 2024

DOI: 10.1002/cam4.7212 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Daniel Sanghoon Shin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology-Oncology, VAGLAHS/David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los…. Hauptthemen laut MEDLINE: CTLA-4 Antigen, Immune Checkpoint Inhibitors, Tumor Microenvironment, Head and Neck Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, CSRD VA, American Society of Clinical Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A phase I clinical study for patients with locally advanced H&N cancer with a new class of botanical drug APG‐157 provided hints of potential synergy with immunotherapy. We sought to evaluate the efficacy of the combination of APG‐157 and immune checkpoint inhibitors.

Methods

CCL23, UM‐SCC1 (human), and SCCVII (HPV−), MEER (HPV+) (murine) H&N cancer cell lines were utilized for in vitro and in vivo studies. We measured tumor growth by treating the mice with APG‐157, anti‐PD‐1, and anti‐CTLA‐4 antibody combinations (8 groups). The tumor microenvironments were assessed by multi‐color flow cytometry, immunohistochemistry, and RNA‐seq analysis. Fecal microbiome was analyzed by 16S rRNA sequence.

Results

Among the eight treatment groups, APG‐157 + anti‐CTLA‐4 demonstrated the best tumor growth suppression ( p = 0.0065 compared to the control), followed by anti‐PD‐1 + anti‐CTLA‐4 treatment group ( p = 0.48 compared to the control). Immunophenotype showed over 30% of CD8+ T cells in APG‐157 + anti‐CTLA‐4 group compared to 4%–5% of CD8+ T cells for the control group. Differential gene expression analysis revealed that APG‐157 + anti‐CTLA‐4 group showed an enriched set of genes for inflammatory response and apoptotic signaling pathways. The fecal microbiome analysis showed a substantial difference of lactobacillus genus among groups, highest for APG‐157 + anti‐CTLA‐4 treatment group. We were unable to perform correlative studies for MEER model as there was tumor growth suppression with all treatment conditions, except for the untreated control group.

Conclusions

The results indicate that APG‐157 and immune checkpoint inhibitor combination treatment could potentially lead to improved tumor control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CTLA-4 AntigenImmune Checkpoint InhibitorsTumor MicroenvironmentHead and Neck NeoplasmsAnimalsMiceCell Line, TumorHumansFemaleAntineoplastic Combined Chemotherapy ProtocolsProgrammed Cell Death 1 ReceptorDisease Models, Animal

Stichwörter der Autor:innen

APG‐157head and neck cancerimmune checkpoint inhibitorsmicrobiometumor microenvironment

Substanzen

CTLA-4 AntigenImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorCtla4 protein, mouse

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology-Oncology, VAGLAHS/David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, California, USA.
  • Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • Parker Institute for Cancer Immunotherapy, Los Angeles, California, USA.
  • Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California, USA.
  • Department of Chemistry and Biochemistry and the Institute for Quantitative and Computational Biology, UCLA, Los Angeles, California, USA.
  • Department of Louise M. Darling Biomedical Library and The Institute for Quantitative and Computational Biology, UCLA, Los Angeles, California, USA.

ORCID-Profile: Daniel Sanghoon Shin

Förderung

  • BLRD VA
  • CSRD VA
  • American Society of Clinical Oncology
  • U.S. Department of Veterans Affairs

Zitieren

APA

Shin, D. S., Basak, S., Veena, M. S., Comin-Anduix, B., Bhattacharya, A., Dong, T. S., Ko, A., Han, P., Jacobs, J., Moatamed, N. A., Avila, L., Pellegrini, M., Wang, M., & Srivatsan, E. S. (2024). Enhanced CTLA ‐4 blockade anti‐tumor immunity with APG ‐157 combination in a murine head and neck cancer. Cancer Medicine. https://doi.org/10.1002/cam4.7212

Vancouver

Shin DS, Basak S, Veena MS, Comin-Anduix B, Bhattacharya A, Dong TS, et al. Enhanced CTLA ‐4 blockade anti‐tumor immunity with APG ‐157 combination in a murine head and neck cancer. Cancer Medicine. 2024. doi:10.1002/cam4.7212

BibTeX
@article{Shin2024,
  author = {Shin, Daniel Sanghoon and Basak, Saroj and Veena, Mysore S and Comin-Anduix, Begoña and Bhattacharya, Arjun and Dong, Tien S and Ko, Albert and Han, Philip and Jacobs, Jonathan and Moatamed, Neda A and Avila, Luis and Pellegrini, Matteo and Wang, Marilene and Srivatsan, Eri S},
  title = {Enhanced CTLA ‐4 blockade anti‐tumor immunity with APG ‐157 combination in a murine head and neck cancer},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.7212}
}
Kostenlos starten →